11 research outputs found
Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries
Background Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia.
Methods Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0-14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995-99, 2000-04, and 2005-09), sex, and age at diagnosis (< 1, 1-4, 5-9, and 10-14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML).
Findings We analysed data from 89 828 children from 198 registries in 53 countries. During 1995-99, 5-year agestandardised net survival for all lymphoid leukaemias combined ranged from 10.6% (95% CI 3.1-18.2) in the Chinese registries to 86.8% (81.6-92.0) in Austria. International differences in 5-year survival for childhood leukaemia were still large as recently as 2005-09, when age-standardised survival for lymphoid leukaemias ranged from 52.4% (95% CI 42.8-61.9) in Cali, Colombia, to 91.6% (89.5-93.6) in the German registries, and for AML ranged from 33.3% (18.9-47.7) in Bulgaria to 78.2% (72.0-84.3) in German registries. Survival from precursor-cell ALL was very close to that of all lymphoid leukaemias combined, with similar variation. In most countries, survival from AML improved more than survival from ALL between 2000-04 and 2005-09. Survival for each type of leukaemia varied markedly with age: survival was highest for children aged 1-4 and 5-9 years, and lowest for infants (younger than 1 year). There was no systematic difference in survival between boys and girls.
Interpretation Global inequalities in survival from childhood leukaemia have narrowed with time but remain very wide for both ALL and AML. These results provide useful information for health policy makers on the effectiveness of health-care systems and for cancer policy makers to reduce inequalities in childhood survival
Fermentation of Calcium-Fortified Soymilk with Lactobacillus: Effects on Calcium Solubility, Isoflavone Conversion, and Production of Organic Acids
Irigenin exerts anticancer effects on human liver cancer cells via induction of mitochondrial apoptosis and cell cycle arrest
Young Females Exhibit Decreased Coronal Plane Postural Stability Compared to Young Males
The effect of soy isoflavones on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials
LC–ESI–MS based characterisation of isoflavones in soybean (Glycine max (L.) Merr.) from India
Erratum to "Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 396-404]
Objective. Ovarian cancer comprises several histological groups with widely differing levels of survival. We
aimed to explore international variation in survival for each group to help interpret international differences in
survival from all ovarian cancers combined. We also examined differences in stage-specific survival.
Methods. The CONCORD programme is the largest population-based study of global trends in cancer survival,
including data from 60 countries for 695,932 women (aged 15\u201399 years) diagnosed with ovarian cancer during
1995\u20132009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal,
other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival
for each country by histological group. We also analysed data from67 cancer registries for 233,659 women diagnosed
from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated agestandardised
5-year net survival by stage at diagnosis (localised or advanced).
Results. Survival fromtype I epithelial ovarian tumours for women diagnosed during 2005\u201309 ranged from40
to 70%. Survival from type II epithelial tumours was much lower (20\u201345%). Survival fromgermcell tumours was
higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord
stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher
than for advanced disease (80% vs. 30%).
Conclusions. There is wide variation in survival between histological groups, and stage at diagnosis remains an
important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate
histology
Erratum to "The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)" [Gynecol. Oncol. 144 (2017) 405-413]
Objective. Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis.
We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role
this may play in international variation in survival.
Methods. The CONCORD programme is the largest population-based study of global trends in cancer survival.
Data on 681,759 women diagnosed during 1995\u20132009 with cancer of the ovary, fallopian tube, peritoneum and
retroperitonum in 51 countries were included.We categorised ovarian tumours into six histological groups, and
explored the worldwide distribution of histology.
Results. During 2005\u20132009, type II epithelial tumours were the most common. The proportion was much
higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America
(65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared
with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased
from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions
of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time.
Conclusions. The distribution of ovarian cancer histology varieswidely worldwide. Type I epithelial, germcell
and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions